Neuroendocrine differentiation in sporadic CRC and hereditary nonpolyosis colorectal cancer

Disease Markers

Volumn 20, Issue 4-5, 2004, Pages 283-288

  Sun, M H ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

colorectal neoplasm; hereditary nonpolyposis colorectal cancer; neuroendocrine differentiation

Indexed keywords

CISPLATIN; ETOPOSIDE; SOMATOSTATIN DERIVATIVE;

ADENOCARCINOMA; CANCER THERAPY; CARCINOGENESIS; CHEMOTHERAPY; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE ASSOCIATION; HUMAN; NEUROENDOCRINE DISEASE; NEUROENDOCRINE SYSTEM; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION;

EID: 12844282305     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/379053     Document Type: Conference Paper

References (52)

1. G. Pelosi, F. Pasini, A. Sonzogni, F. Maffini, P. Maisonneuve, A. Iannucci, A. Terzi, G. De Manzoni, E. Bresaola and G. Viale, Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma, Cancer 97 (2003), 2487-2497.
2. C.E. Erasmus, W.I. Verhagen, C.A. Wauters and E.J. van Lindert, Brain metastasis from prostate small cell carcinoma: not to be neglected, Can J Neurol Sci 29 (2002), 375-377.
3. M.G. House, C.J. Yeo and R.D. Schulick, Periampullary pancreatic somatostatinoma, Ann Surg Oncol 9 (2002), 869-874.
4. B. Wiedenmann, G. Ahnert-Hilger, L.K. Kvols and E.O. Riecken, New molecular aspects for the diagnosis and treatment of neuroendocrine gastroenteropancreatic tumors, Ann N Y Acad Sci 733 (1994), 515-525.
5. B. Wiedenmann, M. John, G. Ahnert-Hilger and E.O. Riecken, Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system, J Mol Med 76 (1998), 637-647.
6. M.F. Rossier, O. Lesouhaitier, E. Perrier, L. Bockhorn, A. Chiappe and N. Lalevee, Idosterone regulation of T-type calcium channels, J Steroid Biochem Mol Biol 85 (2003), 383-388.
7. U. Syversen, T. Halvorsen, R. Marvik and H.L. Waldum, Neuroendocrine diferentiation in colorectal carcinomas, Eur J Gastroenter Hepat 7 (1995), 667-674.
8. Y. Hamada, A. Oishi, T. Shoji, H. Takada, M. Yamamura and K. Hioki, Endocrine cells and prognosis in patients with colorectal carcinoma, Cancer 69 (1992), 2641-2646.
9. F.T. Bosman, Neuroendocrine cells in non-endocrine tumors: what does it mean? Verhand Deutsch Gesell Pathologie 81 (1997), 62-72.
10. E.D. Staren, V.E. Gould, D.S. Jansson, M. Hyser, G.T. Gooch and S.G. Economou, Neuroendocrine di.erentiation in "poorly di.erentiated" colon carcinomas, Am Surgeon 6 (1990), 412-419.
11. M.J. Gaffey, S.E. Mills and E.E. Lack, Neuroendocrine carcinoma of the colon and rectum. A clinicopathologic, ultrastructural, and immunohistochemical study of 24 cases, Am J Surg Pathol 14 (1990), 1010-1023.
12. T.J. Saclarides, D. Szeluga and E.D. Staren, Neuroendocrine cancers of the colon and rectum. Results of a ten-year experience, Dis Colon Rectum 37 (1994), 635-642.
13. A. Pagani, M. Papotti, G.C. Abbona and G. Bussolati, Chromogranin gene expression in colorectal adenocarcinomas, Mod Path 8 (1995), 626-632.
14. M. Mori, K. Mimori, T. Kamakura, Y. Adachi, Y. Ikeda and K. Sugimachi, Chromogranin positive cells in colorectal carcinoma and transitional mucosa, J Clin Pathol 48 (1995), 754-758.
15. G. Lapertosa, P. Baracchini and F. Delucchi, Prevalence and prognostic significance of endocrine cells in colorectal adenocarcinomas, Pathologica 86 (1994), 170-173.
16. G.B. Secco, E. Campora, R. Fardelli, G. Lapertosa, F. De Lucchi, D. Gianquinto and P. Bonfante, Chromogranin-A expression in neoplastic neuroendocrine cells and prognosis in colorectal cancer, Tumori 82 (1996), 390-393.
17. G.Y. Yao, J.L. Zhou, M.D. Lai, X.Q. Chen and P.H. Chen, Neuroendocrine markers in adenocarcinomas: an investigation of 356 cases, World J Gastroenterol 9 (2003), 858-861.
18. T.J. Saclarides, D. Szeluga and E.D. Staren, Neuroendocrine cancers of the colon and rectum. Results of a ten-year experience, Dis Colon Rectum 37 (1994), 635-642.
19. E.D. Staren, V.E. Gould, W.H. Warren, N.L. Wool, S. Bines, J. Baker, P. Bonomi, D.L. Roseman and S.G. Economou, Neuroendocrine carcinomas of the colon and return: a clinico-pathologic evaluation, Surgery 104 (1988), 1080-1089.
20. D. Jansson, V.E. Gould, G.T. Gooch, H.G. Rittenhouse, S.S. Shin, G.L. Manderino, J.T. Tomita and E.D. Staren, Immunohistochemical analysis of colon carcinomas applying exocrine and neuroendocrine markers, APMIS 96 (1988), 1129-1139.
21. P. Atasoy, A. Ensari, S. Demirci and N. Kursun, Neuroendocrine differentiation in colorectal carcinomas: assessing its prognostic significance, Tumori 89 (2003), 49-53.
22. P. Grabowski, J.S.G. Ahnert-Hilger, H.-D.F.B. Heine, I. Schindler, H.S.G. Berger, M. Zeitz and H. Scherubl, Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum, Virchows Arch 441 (2002), 256-263.
23. M. Abdul and N. Hoosein, Relationship of the interleukin-1 system with neuroendocrine and exocrine markers in human colon cancer cell lines, Cytokine 18 (2002), 86-91.
24. M. Indinnimeo, C. Cicchini, L. Memeo, A. Stazi, C. Provenza, F. Ricci and P.L. Mingazzini, Correlation between chromogranin-A expression and pathological variables in human colon carcinoma, Anticancer Res 22(1A) (2002), 395-398.
25. M.H. Sun, H.F. Lu, Q. Cai and D.R. Shi, Neuroendocrine differentiation of sporadic and hereditary nonpolyposis colorectal cancer. In preparation.
26. T. Shimoda, E. Ishikawa, T. Sano, K. Watanabe and M. Ikegami, Histopathological and immunohistochemical study of neuroendocrine tumors of the rectum, Acta Pathol Jpn 34 (1984), 1059-1077.
27. E. Seretis, A. Gavrill, N. Agnantis, V. Golematis and I.E. Voloudakis-Baltatzis, Comparative study of serotonin and bombesin in adenocarcinomas and neuroendocrine tumors of the colon, Ultrastruct Pathol 25 (2001), 445-454.
28. P. Grabowski, I. Schindler, I. Anagnostopoulos, H.D. Foss, E.O. Riecken, U. Mansmann, H. Stein, G. Berger, H.J. Buhr and H. Scherubl, Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer, Eur J Gastroenterol Hepatol 13 (2001), 405-411.
29. U. Syversen, T. Halvorsen, R. Marvik and H.L. Waldum, Neuroendocrine differentiation in colorectal carcinomas, Eur J Gastroenterol Hepatol 7 (1995), 667-674.
30. R. Onishi, T. Sano, Y. Nakamura, S. Namiuchi, S. Sawada, C. Ihara and A. Shimatsu, Ectopic adrenocorticotropin syndrome associated with undifferentiated carcinoma of the colon showing multidirectional neuroendocrine, exocrine, and squamous differentiation, Virchows Arch 427 (1996), 537-541.
31. N. Tanaka, M. Onda, T. Seya, Y. Kanazawa, Z. Naito, G. Asano and T. Oguro, Establishment and characterization of a human rectal neuroendocrine carcinoma xenograft into nude mice, Digestion 60 (1999), 117-124.
32. A. Ouban, R.A. Nawab and D. Coppola, Diagnostic and pathogenetic implications of colorectal carcinomas with multidirectional differentiation: a report of 4 cases, Clin Colorectal Cancer 1 (2002), 243-248.
33. P. Grabowski, J. Schonfelder, G. Ahnert-Hilger, H.D. Foss, B. Heine, I. Schindler, H. Stein, G. Berger, M. Zeitz and H. Scherubl, Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum, Virchows Arch 441 (2002), 256-263.
34. E.F. Foley, M.J. Gaffey and H.F. Frierson Jr, The frequency and clinical significance of neuroendocrine cells within stage III adenocarcinomas of the colon, Arch Pathol Lab Med 122 (1998), 912-914.
35. H. Kim, J.K. Jung, J.H. Park and C. Park, Immunohistochemical characteristics of colorectal carcinoma with DNA replication errors, J Korean Med Sci 11 (1996), 137-143.
36. S.N. Thibodeau, A.J. French and J.M. Cunningham et al., Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1, Cancer 58 (1998), 1713-1718.
37. C.R. Boland, S.N. Thibodeau and S.R. Hamilton et al., A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res 58 (1998), 5248-5257.
38. M.H. Sun, Q. Cai, X.L. Xu, T.M. Zhang, X.Z. Zhu and D.R. Shi, Neuroendocrine differentiation in multiple carcinomas from a hereditary nonpolyposis colorectal cancer patient. Submitted to British J Cancer.
39. A.O. Vortmeyer, I.A. Lubensky, M.J. Merino, C.Y. Wang, T. Pham, E.E. Furth and Z.P. Zhuang, Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas, J Natl Cancer Inst 89 (1997), 1448-1453.
40. V.E. Gould and G. Chejfec, Neuroendocrine carcinomas of the colon. Ultrastructural and biochemical evidence of their secretory function, Am J Surg Pathol 2 (1978), 31-38.
41. T. Ohmori, S. Asahi, C. Sato, F. Maki, A. Masumoto and K. Okada, Bcl-2 protein expression and gut neurohormonal polypeptide/ainine production in colorectal carcinomas and tumor-neighboring mucosa, which closely correlate to the occurrence of tumor, Histol Histopathol 14 (1999), 37-44.
42. M.J. Anasagasti, E. Olaso, F. Calvo, L. Mendoza, J.J. Martin, J. Bidaurrazaga and F. Vidal-Vanaclocha, Interleukin 1-dependent and -independent mouse melanoma metastases, J Natl Can Inst 89 (1997), 645-651.
43. B.Y. Li, D. Mohanraj, M.C. Olson, M. Moradi, L. Twiggs, L.F. Carson and S. Ramakrishnan, Human ovarian epithelial cancer cells cultures in vitro express both interleukin 1 alpha and beta genes, Cancer Res 52 (1992), 2248-2252.
44. G.F. Paciotti and L. Tamarkin, Interleukin-1 directly regulatesn hormone-dependent human breast cancer cell proliferation in vitro, Mol Endocrinol 2 (1998), 459-464.
45. P. Thomas, A. Gangopadhyay, G. Steele Jr., C. Andrews, H. Nakazato, S. Oikawa and J.M. Jessup, The effect of transfection of the CEA gene on the metastatic behavior of the human colorectal cancer cell line MIP-101, Cancer Lett 92 (1995), 59-66.
46. J.L. Ku, K.A. Yoon, D.Y. Kim and J.G. Park, Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines, Eur J Cancer 35(12) (1999), 1724-1729.
47. J. Huang, C. Behrens, I.I. Wistuba, A.F. Gazdar and J. Jagirdar, Clonality of combined tumors, Arch Pathol Lab Med 126 (2002), 437-441.
48. A.O. Vortmeyer, I.A. Lubensky, M.J. Merino, C.Y. Wang, T. Pham, E.E. Furth and Z. Zhuang, Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas, J Natl Cancer Inst 89 (1997), 1448-1453.
49. A. Ubiali, A. Benetti, M. Papotti, V. Villanacci and G. Rindi, Genetic alterations in poorly differentiated endocrine colon carcinomas developing in tubulo-villous adenomas: a report of two cases, Virchows Arch 439 (2001), 776-781.
50. E. Bajetta, C. Carnaghi, L. Ferrari, I. Spagnoli, V. Mazzaferro and R. Buzzoni, The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours, Digestion 57(Suppl 1) (1996), 72-76.
51. E. Bajetta, G. Procopio, L. Ferrari, L. Catena, M. Del Vecchio and E. Bombardieri, Update on the treatment of neuroendocrine tumors, Expert Rev Anticancer Ther 3 (2003), 631-642.
52. M. HÖpfner, A.P. Sutter, N.I. Beck, B. Barthel, K. Maaser, M.C. Jockers-ScherÜbl, M. Zeitz and Hans ScherÜbl, Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells, Int J Cancer 101 (2002), 210-216.